ADVB logo

ADVANCED BIOMED INC

ADVBNASDAQ
๐Ÿ† #5106 by market capUS Equity
$1.65โ–ผ $0.10 (โˆ’5.71%)
Market closed ยท at close
๐Ÿ””
Track ADVB
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 5.7%
7dโ–ผ 28.9%
14dโ–ผ 22.2%
30dโ–ผ 53.0%
ytdโ–ผ 74.5%
1yโ–ผ 77.2%
๐ŸฆMarket Cap
$3M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
0.0%
Slowing
๐Ÿ“ŠGross Margin
-4619.4%
Thin
๐Ÿ’ตFCF Margin
-609.5%
Thin
โš–๏ธP/S Ratio
21.4x
Expensive
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$1.58 โ€“ $1.76
52-Week Range
$1.58 โ€“ $24.23
Volume (shares)
16,712
Avg Volume (shares)
โ€”
Shares Outstanding
1.7M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$127,637
Last Q Revenue
โ€”
P/E Ratio
-13.8
P/S Ratio
21.4x
EPS (TTM)
$3.68
Dividend Yield
0.00%
ADVB logo

ADVANCED BIOMED INC

ADVB
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ADVANCED BIOMED INC

Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates